Trinity Biotech (NASDAQ:TRIB) shares are in focus after the diagnostics specialist reported a return to positive adjusted EBITDA and secured a major 9 million-unit order for its flagship HIV screening product.
The order for the WHO-prequalified TrinScreen HIV rapid test marks a significant volume win for the Dublin-based company, with fulfillment slated for the current quarter and the first quarter of 2026.
The 9 million-unit commitment follows a period of stabilization in global health funding and reflects the success of Trinity’s shift toward high-volume, cost-effective manufacturing.
The company recently received critical World Health Organization (WHO) approval for its outsourced manufacturing model, a move designed to lower production costs and improve scalability as it targets large-scale screening programs in emerging markets.
Financial results for the third quarter of 2025 underscore the turnaround.
Revenue climbed to $14.3 million, a 32% increase over the second quarter, driven by a $2.1 million surge in rapid HIV test sales and a strong performance in its hemoglobin product line.
Improved operational efficiency pushed gross margins to 45.2%, helping the company achieve an adjusted EBITDA of $0.5 million—a sharp reversal from the $2.1 million loss reported in the prior period.